MP78-17 A PHASE II STUDY TO EVALUATE OUTPATIENT, TRANSRECTALLY-DELIVERED, MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: 9 YEAR INTERIM RESULTS (NCT 02243033)

INTRODUCTION AND OBJECTIVES:In the United States alone, new prostate cancer cases for 2018 were estimated at 164,690 and deaths at 29,430[1]. Focal therapies for prostate cancer are increasingly being explored and new treatments for salvage patients are being studied. Our objective is to investigate the efficacy of using MR-guided laser focal therapy for MR-visible prostate cancer utilizing a transrectal approach for laser applicator placement and therapy delivery in an outpatient setting. Lasers have been used for soft tissue necrotization for decades[2]. A commercially available MR-guided biopsy system allows insertion of a laser fiber into biopsy-proven cancer for ablation of MR-visible tumor.METHODS:All MRI-guided therapy was delivered using a 1.5 Tesla Philips Achieva XR system (Philips Healthcare, Best, The Netherlands) for both image acquisition and real-time thermometry. DynaCAD and DynaLOC (Invivo, Orlando, FL, USA) software were used for image analysis and laser fiber placement planning. Laser f...